Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Mylan Nv Ord Shs (MYL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 21,166,640
  • Shares Outstanding, K 536,000
  • Annual Sales, $ 11,077 M
  • Annual Income, $ 480,000 K
  • 36-Month Beta 1.28
  • Price/Sales 1.86
  • Price/Cash Flow 5.04
  • Price/Book 1.76

Price Performance

See More
Period Period Low Period High Performance
1-Month
37.28 +5.10%
on 07/07/17
39.80 -1.56%
on 07/21/17
+0.91 (+2.38%)
since 06/21/17
3-Month
36.50 +7.34%
on 06/15/17
40.67 -3.66%
on 06/09/17
+2.35 (+6.38%)
since 04/21/17
52-Week
33.60 +16.61%
on 11/03/16
50.40 -22.26%
on 08/09/16
-7.68 (-16.39%)
since 07/21/16

Most Recent Stories

More News
What Lies in Store for Glaxo (GSK) this Earnings Season?

The performance of GlaxoSmithKline plc's (GSK) new products is likely to be good. Vaccines acquired from Novartis are likely to drive revenues and ease the impact of the loss of key drug, Advair.

MYL : 39.19 (-0.76%)
NVO : 42.87 (-1.56%)
PFE : 33.49 (-0.15%)
GSK : 42.60 (-0.40%)
Mylan Nv (MYL) Breaks Through Resistance at $38.62

Shares of Mylan Nv (NASDAQ:MYL) have bullishly opened above the pivot of $38.19 today and have reached the first resistance level of $38.62. Investors may be interested in a cross of the next upside pivot...

MYL : 39.19 (-0.76%)
Theravance Biopharma and Mylan Announce Positive Results from 12-Month Phase 3 Safety Study of Revefenacin (TD-4208) in Patients with Chronic Obstructive Pulmonary Disease (COPD)

Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") and Mylan N.V. (NASDAQ, TASE: MYL) ("Mylan") today announced positive results from a 12-month Phase 3 safety study of revefenacin (TD-4208),...

MYL : 39.19 (-0.76%)
TBPH : 38.01 (+0.61%)
Theravance Biopharma and Mylan Announce Positive Results from 12-Month Phase 3 Safety Study of Revefenacin (TD-4208) in Patients with Chronic Obstructive Pulmonary Disease (COPD)

Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma") and Mylan N.V. (NASDAQ, TASE: MYL) ("Mylan") today announced positive results from a 12-month Phase 3 safety study of revefenacin (TD-4208),...

MYL : 39.19 (-0.76%)
TBPH : 38.01 (+0.61%)
Mylan Nv Falls 1.76% on Heavy Volume: Watch For Potential Rebound

Mylan Nv (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $37.87 to a high of $38.59. Yesterday, the shares fell 1.8%, which took the trading range below the 3-day low of $38.65 on...

MYL : 39.19 (-0.76%)
Mylan Nv Set to Possibly Rebound After Yesterday's Selloff of 1.76%

Mylan Nv (NASDAQ:MYL) traded in a range yesterday that spanned from a low of $37.87 to a high of $38.59. Yesterday, the shares fell 1.8%, which took the trading range below the 3-day low of $38.65 on...

MYL : 39.19 (-0.76%)
Mylan's Biosimilar Herceptin Gets FDA Advisory Committee Nod

Mylan N.V. (MYL) and partner, Biocon Ltd. announced that the FDA Oncologic Drugs Advisory Committee (ODAC) unanimously recommended approval of its biosimilar version of Roche's (RHHBY) breast cancer drug...

MYL : 39.19 (-0.76%)
AGN : 249.98 (+0.37%)
RHHBY : 32.0800 (-0.37%)
AMGN : 179.86 (+0.30%)
Pharma Stock Roundup: FDA Panel Votes for Novartis CAR-T Drug, SNY to Buy Vaccines Co.

Novartis (NVS) was in the limelight this week with its CAR-T cell therapy receiving the support of an FDA advisory panel.

MYL : 39.19 (-0.76%)
AZN : 33.97 (+0.24%)
JNJ : 135.21 (-1.00%)
LLY : 84.73 (-0.02%)
NVS : 84.91 (-0.60%)
PFE : 33.49 (-0.15%)
SNY : 47.50 (-1.17%)
Mylan Nv (MYL) Crosses Pivot Point Resistance at $38.83

Shares of Mylan Nv (NASDAQ:MYL) opened today above their pivot of $38.36 and have already reached the first level of resistance at $38.83. Should the shares continue to rise, the resistance pivots of...

MYL : 39.19 (-0.76%)
Today's Research Reports on Stocks to Watch: ACADIA Pharmaceuticals Inc. and Mylan N.V.

NEW YORK, NY / ACCESSWIRE / July 13, 2017 / U.S. markets rose Wednesday as investors reacted positively to Federal Reserve Chairwoman Janet Yellen's congressional testimony. The Dow Jones Industrial Average...

MYL : 39.19 (-0.76%)
ACAD : 30.48 (+1.30%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More

Business Summary

Mylan NV is a pharmaceutical company. The company develops, licenses, manufactures, markets and distributes generic and specialty pharmaceuticals. It operates primarily in the United States, Canada, Europe, the Middle East, Africa, India, Australia, Japan and New Zealand. Mylan NV, formerly known as...

See More

Support & Resistance

2nd Resistance Point 40.19
1st Resistance Point 39.84
Last Price 39.19
1st Support Level 38.88
2nd Support Level 38.27

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.